Paclitaxel and carboplatin combination chemotherapy has remained the standard of care in the front-line therapy of advanced epithelial ovarian cancer during the last decade. Maintenance chemotherapy has not been proven to impact on overall survival. Acceptable alternatives include weekly paclitaxel plus 3-weekly carboplatin, the addition of bevacizumab to 3-weekly carboplatin and paclitaxel, and intraperitoneal chemotherapy. In particular, anti-angiogenic therapy has been identified as the most promising targeted therapy, and the addition of bevacizumab to first-line chemotherapy followed by a maintenance period of bevacizumab in monotherapy has shown to prolong progression-free survival. This was considered the proof of concept of the value of anti-angiogenic therapy in the front-line of ovarian cancer, and the results of two additional clinical trials with anti-angiogenic tyrosine kinase inhibitors have shown results in the same direction.
Background
Surgery is an essential part of the treatment of advanced ovarian cancer. The main objective of primary surgery is to obtain a complete resection of all macroscopically visible disease. Since the majority of patients despite complete resection will recur, chemotherapy is necessary to improve outcome.
The combination of paclitaxel 175 mg/m 2 and carboplatin area under the curve (AUC) 5 or 6, administered intravenously, every 3 weeks has been the standard of care in front-line therapy of epithelial ovarian cancer (EOC) during the last 15 years [1] . In the mid-1990s, two large, randomized clinical trials demonstrated that the combination of paclitaxel and cisplatin was superior to the regimen of cisplatin and cyclophosphamide [2, 3] . Later on, another three randomized clinical trials confirmed that the substitution of cisplatin by carboplatin in combination with paclitaxel had the same efficacy but a better safety profile and convenience of administration [4] . Unfortunately, median time to progression is not fully satisfactory, with a range of 12-18 months depending on the residual disease after surgery, and a 5-year OS of <35%.
Since the end of the 1990s, several chemotherapy-based strategies have tried to improve the outcome of patients with advanced ovarian cancer. However, neither the substitution of paclitaxel by another drug, such as docetaxel or pegylated liposomal doxorubicin [5] , or the addition of a third drug to the paclitaxel-carboplatin doublet in the form of triplet or sequential doublets were able to obtain better results [6] .
Two different strategies consisting of a change in the route of administration of platinum by intraperitoneal delivery, or the schedule of administration of paclitaxel in a dose-dense regimen of weekly administration, have been shown to improve the outcome of patients with advanced ovarian cancer. However, the results of both strategies are still controversial and have not been widely adopted as standard therapy. Intraperitoneal therapy will be discussed in a separate paper.
Dose-dense chemotherapy consists of more frequent administration of some or all of the drugs of the regimen, usually in a weekly or every other week schedule, sometimes resulting in a higher cumulative dose. This strategy was adopted in a randomized clinical trial called NOVEL launched by the Japanese Gynecologic Oncology Group [7] . Patients with stage IIB-IV EOC were randomized to a standard schedule of paclitaxel 180 mg/m 2 and carboplatin AUC 6 administered every 3 weeks, or the administration of weekly paclitaxel 80 mg/m 2 and carboplatin AUC 6 every 3 weeks. The dose-dense regimen obtained a longer time to progression [28.1 versus 17.5 months; hazard ratio (HR) 0.76; 95% confidence interval (CI) 0.62-0.91; P ¼ 0.0037] and also overall survival (OS; 5-year OS was 58.7% versus 51.1%; HR 0.79; 95% CI 0.63-0.99; P ¼ 0.0448). Despite the results of this trial, the dose-dense regimen has not been widely adopted due to the toxicity reported with this regimen and the potential pharmacogenetic differences between the Japanese and the Caucasian populations. Three large, randomized clinical trials are assessing the dose-dense issue in the Western population-the Italian MITO-7, GOG-262, and ICON8 [8] . The first two could not confirm the value of dosedense therapy. The results of ICON8 are eagerly awaited. In summary, the combination of paclitaxel and carboplatin administered every 3 weeks is still the most accepted backbone chemotherapy for advanced ovarian cancer.
Maintenance therapy has been explored as a strategy to prolong the progression-free interval and OS of patients with advanced ovarian cancer. Unfortunately, all but one trial, all using conventional chemotherapy failed to show some impact on the outcome of patients.
Anti-angiogenic therapy was identified as one of the most promising targeted therapies in ovarian cancer. Neoangiogenesis is a necessary step for tumor proliferation and invasion, as a result of an imbalance between proangiogenic and antiangiogenic factors in favor of the former. One of the most important pathways implicated in the initiation of tumor angiogenesis is the interaction of vascular endothelial growth factor (VEGF) with its receptors (VEGFR-1, -2, and -3). In fact, VEGF overexpression has been demonstrated to be an adverse prognostic factor in ovarian carcinoma as it has been associated with tumor progression and shortened OS. Additionally, other factors and pathways such as platelet-derived growth factor (PDGF) or fibroblast growth factor (FGF) have been implicated in ovarian cancer progression, prognosis and resistance to anti-VEGF therapy.
Bevacizumab (Genentech, South San Francisco, CA) is a humanized monoclonal antibody against VEGF-A. It was the first antiangiogenic therapy used in the clinic and the most extensively studied antiangiogenic agent in ovarian cancer.
Two large, prospective, randomized clinical trials have included bevacizumab in the front-line therapy of ovarian, primary peritoneal or fallopian tube cancer in combination with standard chemotherapy followed by a maintenance period with bevacizumab [9, 10] .
The GOG-218 trial was a double-blind, randomized clinical trial that included patients with ovarian cancer, fallopian tube cancer or primary peritoneal carcinomatosis with suboptimal or optimal cytoreduction (<1 cm) but with residual macroscopic tumor after front-line debulking surgery [9] . A total of 1873 patients were included. All patients received standard chemotherapy with intravenous paclitaxel 175 mg/m 2 and carboplatin AUC 6 administered every 3 weeks for six cycles, and were randomized to one of the following three arms: the control arm consisted of the administration of intravenous placebo in cycles 2 through 22; the second group, also called the 'bevacizumab initiation group', consisted of the administration of bevacizumab 15 mg/kg every 3 weeks in cycles 2 through 6 concurrently with chemotherapy followed by placebo from cycles 7 to 22; and the bevacizumab-throughout group was chemotherapy with bevacizumab 15 mg/kg added in cycles 2 through 6 followed by a period of maintenance from cycles 7 to 22 (15 months in total). The main end point of the GOG trial was progression-free survival (PFS) determined by CA-125 GCIG progression criteria or radiological progression according to RECIST criteria. The bevacizumab initiation group did not obtain any significant benefit in outcome over the control group. However, the bevacizumab-throughout group had a significantly longer PFS than the control group (14.1 versus 10.3 months; HR 0.71; 95% CI 0.625-0.824; P < 0.001). The maximal separation of the PFS curves for the bevacizumab-throughout group and the control group occurred at 15 months, with convergence 9 months later.
In the ICON7 trial, a total of 1528 patients with EOC, fallopian tube cancer or primary peritoneal carcinomatosis with FIGO (International Federation of Gynecology and Obstetrics) highrisk stage I (defined as grade 3 or clear cell histology) to stage IV were randomized to one of the following arms: the standard arm was intravenous paclitaxel 175 mg/m 2 and carboplatin AUC 6 every 3 weeks, and the experimental arm was the same chemotherapy regimen with bevacizumab 7.5 mg/kg every 3 weeks added from cycles 1 to 18 (a total of 12 months) [10] . Patients were stratified according to the extension of the disease and debulking (stage I-III with optimal debulking <1 cm versus stage I-III with suboptimal debulking >1 cm versus inoperable stage III and IV), timing of treatment initiation (<4 weeks versus >4 weeks) and GCIG group. The primary end point in this trial was also the PFS, but in this case progression was defined by RECIST criteria only. The median PFS was 17.3 months in the standard therapy group and 19.0 months in the bevacizumab group. A comparison of Kaplan-Meier curves for PFS showed a significant difference between the two groups (estimated HR for progression or death in the bevacizumab group, 0.81; 95% CI 0.70-0.94; P ¼ 0.004). The effect of bevacizumab was maximal at 12 months, with an improvement in PFS at this time of 15.1% compared with the standard arm. No significant differences in OS have been found in GOG-218 or ICON7.
Regarding safety, the most common side-effect associated with the administration of bevacizumab was the development of grade 2 hypertension (22.9% in GOG-218 and 18.9% in ICON7). In GOG-218, there were no significant differences among the three groups in the rates of other adverse events, including gastrointestinal perforation (GIP) or fistula, proteinuria of grade 3 or greater, neutropenia of grade 4 or greater or febrile neutropenia, venous or arterial thrombosis, and wound disruption. Similar conclusions were obtained in ICON7, except for grade 3 thromboembolic events, which were 7% with bevacizumab versus 3% with standard therapy. Finally, the rate of GIP was observed in only 1% of patients in ICON7 and <2% in the GOG-218 trial.
The differences in patient population between the two studies could have influenced the magnitude of the impact of the intervention. Ten percent of patients included in ICON7 had stage I or IIA disease, and the rate of patients with optimal debulking (defined as residual disease <1 cm) after primary surgery was much higher in ICON7 than in the GOG-218 trial (74% versus 35%, respectively). Moreover, in the ICON7 trial there was a heterogeneous mix of patients with different stages and residual disease after surgery, which means differences in prognosis. In fact, the test for interaction suggests that the size of the effect of bevacizumab differed between patients at high risk for progression and the rest of the study population (P ¼ 0.06), showing a benefit for the high-risk group. A subanalysis of patients at high risk of progression (defined as stage IV or stage III with residual disease >1 cm after surgery) showed that the estimated median PFS was 10.5 months with standard therapy compared with 16 months with the bevacizumab-containing arm (HR for progression or death in the bevacizumab group, 0.73; 95% CI 0.60-0.93; P ¼ 0.002), and that OS increased from 28.8 months in those receiving the standard-therapy to 36.6 months in those receiving bevacizumab (HR for death in the bevacizumab group, 0.64; 95% CI 0.48-0.85; P ¼ 0.002).
In the multinational prospective single-arm ROSIA study, eligible patients had FIGO stage IIB to IV or grade 3 stage I to IIA EOC without clinical signs or symptoms of gastrointestinal obstruction or history of abdominal fistula, GIP, or intraabdominal abscess within the preceding 6 months. Prior neoadjuvant chemotherapy was permitted. After debulking surgery, patients received bevacizumab 15 (or 7.5) mg/kg every 3 weeks (q3w) with 4-8 cycles of paclitaxel (investigator's choice of 175 mg/m 2 q3w or 80 mg/m 2 weekly) plus carboplatin AUC 5-6 q3w. Single-agent bevacizumab was continued until progression or up to 24 months. A total of 1021 patients were enrolled and treated for more than 15 months in 53%. Median PFS was 25.5 months (95% CI 23.7-27.6 months), which is the longest PFS reported for front-line bevacizumab-containing therapy. This single arm study suggested that extended bevacizumab may improve PFS without substantially compromising safety [11] . This important hypothesis has to be demonstrated by a clinical trial which has already closed enrolment: the BOOST trial.
Trebananib (AMG-386; Amgen, Thousand Oaks, CA) is a first-inclass investigational peptide-Fc fusion protein peptibody that neutralizes the interaction between the Tie2 receptor and angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2). The angiopoietin axis promotes vascularization in ovarian cancer by a different pathway than the VEGF-VEGFR interaction. Trebananib has entered an extensive program for clinical development, known as TRINOVA, which includes three different studies. However, inclusion of trebananib into the upfront therapy (ENGOT-ov6/TRINOVA-3) failed to meet the primary end point of improved PFS [12] .
Pazopanib (Votrient TM ; GlaxoSmithKline, London, UK) is an oral small-molecule angiogenesis inhibitor targeting VEGF receptors (VEGFR-1, -2, and -3), PDGF receptors (PDGFR-a and b), FGF receptors (FGFR-1 and -3) , and c-Kit. Based on the antitumor activity shown in patients with recurrent and small-volume disease, pazopanib was investigated as maintenance therapy in frontline therapy in an international cooperative AGO-OVAR-16 trial led by the AGO group (Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovar). In this study, patients without progression after first-line therapy based on platinum/taxanes and a tumor of less than 2 cm in baseline evaluation were randomized to maintenance with placebo or pazopanib. Results demonstrated that pazopanib as maintenance therapy had a statistically significant PFS benefit (HR 0.766; 95% CI 0.64-0.91; P ¼ 0.0021; median 17.9 versus 12.3 months, respectively), but no effect on OS [13] .
Nintedanib (BIBF 1120; Boehringer Ingelheim, Ingelheim, Germany), a 6-methoxycarbonyl-substituted indolinone, is a potent inhibitor of VEGFR-1, -2, and -3, as well as PDGF receptors (PDGFR-a and -b) and FGF receptors (FGFR-1, -2, and -3).
Inhibition of angiogenesis in front-line and maintenance treatment of ovarian cancer Additionally, it inhibits Src and fms-like tyrosine kinase 3 (FLT-3). Nintedanib was studied in the international cooperative phase III trial AGO-OVAR 12/LUME-OVAR-1. This trial included patients with an initial diagnosis of ovarian, primary peritoneal or fallopian tube cancer stage IIB-IV after initial debulking surgery, or with only biopsy for patients with stage IV in whom surgery was not considered an option. A total of 1366 patients were randomized to paclitaxel/carboplatin every 3 weeks with placebo or nintedanib for 6 cycles followed by maintenance therapy with placebo or nintedanib for 120 weeks (including the period of concurrence with chemotherapy) if no progression or intolerance was detected. Nintedanib added to paclitaxel and carboplatin chemotherapy significantly increased PFS from 16.6 to 17.2 months (HR 0.84; 95% CI 0.72-0.98; P ¼ 0.0239). OS data have not been reported yet [14] .
Discussion Conclusion
Front-line chemotherapy for EOC has not changed in the last decade and the combination of paclitaxel and carboplatin administered every 3 weeks has remained the standard of care [15] . Alternative schedules, such as, for instance, intraperitoneal administration of chemotherapy or dose-dense regimen, are still controversial and have not been adopted widely in clinical practice. This scenario has recently changed due to the introduction of targeted agents, especially antiangiogenic agents. Data from two large, randomized clinical trials have shown that adding bevacizumab to the chemotherapy regimen followed by a maintenance period of bevacizumab prolongs the PFS, mainly in patients considered at high risk of relapse. The results of the clinical trials with bevacizumab have been considered the proof of concept of the value of antiangiogenic therapy in the front-line therapy of ovarian cancer. The addition of bevacizumab to paclitaxel and carboplatin can be considered as standard of care at least in patients with FIGO stage IIIb or higher. However, several questions have risen about the optimal setting, dose and duration of bevacizumab. Additionally, we already have positive results of other phase III trials with antiangiogenic agents, in front-line (pazopanib and nintedanib) therapy. The great challenge for the near future will be the selection of patients with advanced ovarian cancer obtaining more benefit from these different options in front-line therapy and in recurrent disease. More recently in recurrent ovarian cancer immune checkpoint inhibitors and PARP inhibitors have demonstrated interesting results with long-term responses. The inclusion of these new agents in the chemotherapy backbone is therefore highly interesting and is currently under investigation in large phase III trials.
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